Managing Toxicities of Hydroxyurea in Patients With PV
Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.
EP: 1.Risk Assessment in Patients With Polycythemia Vera (PV)
EP: 2.Reducing Risk of Disease Progression in Patients With PV
EP: 3.Typical Presentation of a Patient With PV
EP: 4.Importance of Bone Marrow Biopsy For Diagnosis of PV
EP: 5.Reducing Risk of Thrombosis in Patients With PV
EP: 6.Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV
Now Viewing
EP: 7.Managing Toxicities of Hydroxyurea in Patients With PV
EP: 8.Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV
EP: 9.Key Trials in the Treatment of PV
EP: 10.Treatment Approaches for High-Risk Patients With PV
EP: 11.Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV
EP: 12.Ruxolitinib in the Treatment of PV
EP: 13.Future Perspectives in the Treatment of Polycythemia Vera
Related Videos
Related Content
FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
September 19th 2022
Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia
September 21st 2023
FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
September 19th 2022
Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia
September 21st 2023
FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
September 19th 2022
